Evidence map›Paper›PMID 40119436›Full record

ArticleJournal of nanobiotechnology2025

Rationally designed NIR-II excitable and endoplasmic reticulum-targeted molecular phototheranostics for imaging-guided enhanced photoimmunotherapy of triple-negative breast cancer.

Fen Liu, Qiang Kang, Hao Xiao, Yinying Liu, Sengyou Tan, Kun Fan, Jianchun Peng, Xiaofeng Tan, Guilong Wu, Qinglai Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fen Liu *Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Qiang Kang *Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Hao XiaoDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Yinying LiuDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Sengyou TanDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Kun FanDepartment of Radiology, The Second Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Jianchun PengDepartment of Radiology, The Second Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Xiaofeng TanDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. tanxiaofeng@usc.edu.cn.
Guilong WuDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. 2018000014@usc.edu.cn.
Qinglai YangDepartment of Hepatopancreatobiliary Surgery, the First Affiliated Hospital & Center for Molecular Imaging Probe, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. qingyu513@usc.edu.cn.

Funding

Hengyang Science and Technology Bureau 2020 Guidance Project 20jh052768Key Research and Development Program of Hunan Province, China 2022SK2053National Science Foundation of China 22374065Natural Science Foundation of Hunan Province of China 2024JJ6374Natural Science Foundation of Hunan Province of China 2025JJ50563Outstanding Youth Foundation of Hunan Province 2024JJ2047
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by an extremely poor prognosis. Photoimmunotherapy has emerged as a promising strategy for the treatment of TNBC. This approach works by selectively destroying tumor cells, releasing tumor-associated antigens, activating the immune system, and effectively inhibiting tumor proliferation and metastasis. However, the majority of current phototheranostic approaches are hindered by limited tissue penetration in the first near-infrared (NIR-I) and ultraviolet-visible (UV-Vis) regions. Additionally, due to the lack of specific subcellular targets, it may be difficult to effectively treat deep-seated lesions with ambiguous and extensive boundaries caused by TNBC metastases. Consequently, the development of effective, deep-penetrating, organelle-targeted phototheranostics is essential for enhancing treatment outcomes in TNBC. This work proposes a novel molecular design strategy of NIR-II phototheranostics to realize planar rigid conjugation and alkyl chain functionalization. The di-hexaalkyl chains in a vertical configuration on the donor (4H-cyclopenta[2,1-b:3,4-b'] dithiophene) and shielding units (fluorene) are introduced to construct a S-D-A-D-S type NIR-II phototheranostics (IR-FCD). The planar and rigid structure of IR-FCD exhibits a robust intramolecular charge transfer capability, a lower band gap, enhanced photon absorption properties, and significant steric hindrance from vertically arranged alkyl chains to minimize non-radiative energy loss. By incorporating N-(but-3-yn-1-yl)-4-methylbenzenesulfonamide at the terminus of an elongated alkyl chain, followed by self-assembly into DSPE-S-S-PEG2000, NIR-II excitable phototheranostics (IR-FCD-Ts NPs) with endoplasmic reticulum (ER) targeting capability were successfully synthesized for imaging-guided photoimmunotherapy of TNBC. The IR-FCD-Ts NPs demonstrate exceptional optical characteristics, with maximum absorption at 1068 nm (extending to 1300 nm) and emission at 1273 nm (extending to 1700 nm), along with a high molar absorption coefficient of 2.76*10

Indexed as

Endoplasmic ReticulumImmunotherapyPhototherapyTheranostic NanomedicineTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansInfrared RaysMiceMice, Inbred BALB CEndoplasmic reticulumIntermolecular π–π stacking interactionNIR-IIPhototheranosticsTriple-negative breast cancer

Identifiers

PMID40119436
PMCPMC11929327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.